<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340885</url>
  </required_header>
  <id_info>
    <org_study_id>PANUC - Lou</org_study_id>
    <secondary_id>5P50NS062684-02</secondary_id>
    <nct_id>NCT01340885</nct_id>
  </id_info>
  <brief_title>Cognitive Decline in Non-demented PD</brief_title>
  <official_title>Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relationship between attention and quality of
      life and how rivastigmine and atomoxetine alter attention in non-demented persons with
      Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as
      PD progresses. Attention deficits in PD patients with dementia strongly predict the
      impairment of their daily living activities.

      Previous studies have shown that atomoxetine improves PD executive dysfunction and
      rivastigmine improves attention deficits in PD patients with dementia without worsening the
      motor symptoms.

      The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention
      and quality of life in PD patients without disabling cognitive impairment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attention Network Effects</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 weeks</time_frame>
    <description>PDQ-39</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop Color Word Test</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Sleepiness</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>atomoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Strattera 10-30 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivastigimine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exelon 1.5-4.5 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Strattera</intervention_name>
    <description>10-30 mg b.i.d. for 6 weeks</description>
    <arm_group_label>atomoxetine</arm_group_label>
    <other_name>atomoxetine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exelon</intervention_name>
    <description>1.5-4.5 mg b.i.d. for 6 weeks</description>
    <arm_group_label>rivastigimine</arm_group_label>
    <other_name>rivastigmine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2-6 pills for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Parkinson's disease

          -  Respond to levodopa therapy

        Exclusion Criteria:

          -  Dementia

          -  Psychiatric disorders including anxiety disorders, dissociative disorders, mood
             disorders, schizophrenia and related disorders, or ADD/ADHD

          -  Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver
             disease, kidney or renal failure or others that might require hospitalization

          -  Evidence for another neurological disease (history of seizures, Alzheimer disease,
             multiple sclerosis or other movement disorders);

          -  Currently using any of the study drugs;

          -  Colorblindness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jau-Shin Lou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <results_first_submitted>June 17, 2020</results_first_submitted>
  <results_first_submitted_qc>June 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2020</results_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jau-Shin Lou</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>attention</keyword>
  <keyword>mild cognitive impairment</keyword>
  <keyword>dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atomoxetine</title>
          <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Rivastigimine</title>
          <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
      <group_list>
        <group group_id="B1">
          <title>Atomoxetine</title>
          <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Rivastigimine</title>
          <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Attention Network Effects</title>
        <time_frame>6 weeks</time_frame>
        <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rivastigimine</title>
            <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Attention Network Effects</title>
          <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>PDQ-39</description>
        <time_frame>6 weeks</time_frame>
        <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rivastigimine</title>
            <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>PDQ-39</description>
          <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroop Color Word Test</title>
        <time_frame>6 weeks</time_frame>
        <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rivastigimine</title>
            <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Stroop Color Word Test</title>
          <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue</title>
        <time_frame>6 weeks</time_frame>
        <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rivastigimine</title>
            <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue</title>
          <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression</title>
        <time_frame>6 weeks</time_frame>
        <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rivastigimine</title>
            <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Depression</title>
          <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Sleepiness</title>
        <time_frame>6 weeks</time_frame>
        <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Atomoxetine</title>
            <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rivastigimine</title>
            <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Sleepiness</title>
          <population>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atomoxetine</title>
          <description>Strattera 10-30 mg b.i.d.
Strattera: 10-30 mg b.i.d. for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Rivastigimine</title>
          <description>Exelon 1.5-4.5 mg b.i.d.
Exelon: 1.5-4.5 mg b.i.d. for 6 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>sugar pill
Placebo: 2-6 pills for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Diana Dimitrova</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-7269</phone>
      <email>dimitrov@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

